Suresh K Mittal

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11078185/publications.pdf

Version: 2024-02-01

68 papers	2,972 citations	159585 30 h-index	168389 53 g-index
68 all docs	68 docs citations	68 times ranked	2948 citing authors

#	Article	IF	Citations
1	Influenza Virus Infects and Depletes Activated Adaptive Immune Responders. Advanced Science, 2021, 8, e2100693.	11.2	7
2	Nonhuman Adenoviral Vector-Based Platforms and Their Utility in Designing Next Generation of Vaccines for Infectious Diseases. Viruses, 2021, 13, 1493.	3.3	9
3	Innate lymphoid cells (ILC) in SARS-CoV-2 infection. Molecular Aspects of Medicine, 2021, 80, 101008.	6.4	10
4	Loss of smarcad1a accelerates tumorigenesis of malignant peripheral nerve sheath tumors in zebrafish. Genes Chromosomes and Cancer, 2021, 60, 743-761.	2.8	3
5	A recombinant bovine adenoviral mucosal vaccine expressing mycobacterial antigen-85B generates robust protection against tuberculosis in mice. Cell Reports Medicine, 2021, 2, 100372.	6.5	16
6	Adenoviral vectorâ€based platforms for developing effective vaccines to combat respiratory viral infections. Clinical and Translational Immunology, 2021, 10, e1345.	3.8	14
7	Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines. Vaccines, 2020, 8, 574.	4.4	40
8	A potential approach for assessing the quality of human and nonhuman adenoviral vector preparations. Canadian Journal of Veterinary Research, 2020, 84, 314-318.	0.2	0
9	Current Use of Adenovirus Vectors and Their Production Methods. Methods in Molecular Biology, 2019, 1937, 155-175.	0.9	16
10	Longevity of adenovirus vector immunity in mice and its implications for vaccine efficacy. Vaccine, 2018, 36, 6744-6751.	3.8	15
11	A Bovine Adenoviral Vector-Based H5N1 Influenza -Vaccine Provides Enhanced Immunogenicity and Protection at a Significantly Low Dose. Molecular Therapy - Methods and Clinical Development, 2018, 10, 210-222.	4.1	14
12	Identification of RECK as an evolutionarily conserved tumor suppressor gene for zebrafish malignant peripheral nerve sheath tumors. Oncotarget, 2018, 9, 23494-23504.	1.8	4
13	KANK1 inhibits cell growth by inducing apoptosis through regulating CXXC5 in human malignant peripheral nerve sheath tumors. Scientific Reports, 2017, 7, 40325.	3.3	23
14	Vaccine approaches conferring cross-protection against influenza viruses. Expert Review of Vaccines, 2017, 16, 1141-1154.	4.4	41
15	Adenoviral E4 34K protein interacts with virus packaging components and may serve as the putative portal. Scientific Reports, 2017, 7, 7582.	3.3	10
16	155R is a novel structural protein of bovine adenovirus type 3, but it is not essential for virus replication. Journal of General Virology, 2017, 98, 749-753.	2.9	2
17	Adenovirus vector-based multi-epitope vaccine provides partial protection against H5, H7, and H9 avian influenza viruses. PLoS ONE, 2017, 12, e0186244.	2.5	15
18	Xenogenic Adenoviral Vectors. , 2016, , 495-528.		5

#	Article	IF	Citations
19	Components of Adenovirus Genome Packaging. Frontiers in Microbiology, 2016, 7, 1503.	3.5	61
20	A highly immunogenic vaccine against A/H7N9 influenza virus. Vaccine, 2016, 34, 744-749.	3.8	12
21	Adenoviral L4 33K forms ring-like oligomers and stimulates ATPase activity of IVa2: implications in viral genome packaging. Frontiers in Microbiology, 2015, 6, 318.	3.5	12
22	Efficiency of Airborne Sample Analysis Platform (ASAP) bioaerosol sampler for pathogen detection. Frontiers in Microbiology, 2015, 6, 512.	3.5	11
23	Adenoviral vector expressing murine Î²-defensin 2 enhances immunogenicity of an adenoviral vector based H5N1 influenza vaccine in aged mice. Virus Research, 2013, 177, 55-61.	2.2	8
24	Beta-defensin 2 enhances immunogenicity and protection of an adenovirus-based H5N1 influenza vaccine at an early time. Virus Research, 2013, 178, 398-403.	2.2	24
25	Adenoviral E2 IVa2 protein interacts with L4 33K protein and E2 DNA-binding protein. Journal of General Virology, 2013, 94, 1325-1334.	2.9	18
26	Broadly Protective Adenovirus-Based Multivalent Vaccines against Highly Pathogenic Avian Influenza Viruses for Pandemic Preparedness. PLoS ONE, 2013, 8, e62496.	2.5	41
27	Sequential administration of bovine and human adenovirus vectors to overcome vector immunity in an immunocompetent mouse model of breast cancer. Virus Research, 2012, 163, 202-211.	2.2	12
28	Impact of Preexisting Adenovirus Vector Immunity on Immunogenicity and Protection Conferred with an Adenovirus-Based H5N1 Influenza Vaccine. PLoS ONE, 2012, 7, e33428.	2.5	65
29	EphrinA1â€“EphA2 interactionâ€mediated apoptosis and FMSâ€like tyrosine kinase 3 receptor ligandâ€induced immunotherapy inhibit tumor growth in a breast cancer mouse model. Journal of Gene Medicine, 2012, 14, 77-89.	2.8	17
30	Emerging strategies for EphA2 receptor targeting for cancer therapeutics. Expert Opinion on Therapeutic Targets, 2011, 15, 31-51.	3.4	209
31	Persistence and the state of bovine and porcine adenoviral vector genomes in human and nonhuman cell lines. Virus Research, 2011, 161, 181-187.	2.2	5
32	Adenoviral Vector Immunity: Its Implications and Circumvention Strategies. Current Gene Therapy, 2011, 11, 307-320.	2.0	148
33	Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target. Expert Reviews in Molecular Medicine, 2010, 12, e14.	3.9	23
34	Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses. Hum Vaccin, 2010, 6, 178-188.	2.4	52
35	Production of adenovirus vectors and their use as a delivery system for influenza vaccines. Expert Opinion on Biological Therapy, 2010, 10, 1469-1487.	3.1	68
36	Evaluation of innate immunity and vector toxicity following inoculation of bovine, porcine or human adenoviral vectors in a mouse model. Virus Research, 2010, 153, 134-142.	2.2	22

#	Article	IF	Citations
37	Comparative analysis of vector biodistribution, persistence and gene expression following intravenous delivery of bovine, porcine and human adenoviral vectors in a mouse model. Virology, 2009, 386, 44-54.	2.4	42
38	Bovine adenovirus serotype 3 utilizes sialic acid as a cellular receptor for virus entry. Virology, 2009, 392, 162-168.	2.4	36
39	Adenovirus receptors and their implications in gene delivery. Virus Research, 2009, 143, 184-194.	2.2	103
40	Adenoviral Vector-Based Strategies for Cancer Therapy. Current Drug Therapy, 2009, 4, 117-138.	0.3	54
41	Bovine Adenoviral Vectorâ€“based H5N1 Influenza Vaccine Overcomes Exceptionally High Levels of Pre-existing Immunity Against Human Adenovirus. Molecular Therapy, 2008, 16, 965-971.	8.2	68
42	A Broadly Protective Vaccine against Globally Dispersed Clade 1 and Clade 2 H5N1 Influenza Viruses. Journal of Infectious Diseases, 2008, 197, 1185-1188.	4.0	58
43	Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet, The, 2006, 367, 475-481.	13.7	179
44	Modulation of PKR activity in cells infected by bovine viral diarrhea virus. Virus Research, 2006, 116, 69-77.	2.2	25
45	Development of nonhuman adenoviruses as vaccine vectors. Vaccine, 2006, 24, 849-862.	3.8	122
46	Current Strategies and Future Directions for Eluding Adenoviral Vector Immunity. Current Gene Therapy, 2006, 6, 215-226.	2.0	143
47	Expression of EphA2 and Ephrin A-1 in Carcinoma of the Urinary Bladder. Clinical Cancer Research, 2006, 12, 353-360.	7.0	109
48	Immunocompetent mouse model of breast cancer for preclinical testing of EphA2-targeted therapy. Cancer Gene Therapy, 2005, 12, 46-53.	4.6	32
49	Porcine adenovirus serotype 3 internalization is independent of CAR and Î±vÎ²3 or Î±vÎ²5 integrin. Virology, 2005, 332, 157-166.	2.4	26
50	Comparative transduction efficiencies of human and nonhuman adenoviral vectors in human, murine, bovine, and porcine cells in culture. Biochemical and Biophysical Research Communications, 2005, 327, 960-966.	2.1	62
51	Bovine adenovirus type 3 internalization is independent of primary receptors of human adenovirus type 5 and porcine adenovirus type 3. Biochemical and Biophysical Research Communications, 2005, 331, 1478-1484.	2.1	38
52	Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1. Cancer Gene Therapy, 2004, 11, 757-766.	4.6	113
53	Porcine adenoviral vectors evade preexisting humoral immunity to adenoviruses and efficiently infect both human and murine cells in culture. Virus Research, 2004, 105, 127-136.	2.2	52
54	Development and Characterization of Bovine Ã— Human Hybrid Cell Lines That Efficiently Support the Replication of both Wild-Type Bovine and Human Adenoviruses and Those with E1 Deleted. Journal of Virology, 2002, 76, 5882-5892.	3.4	27

#	Article	IF	Citations
55	A 72-bp Internal Deletion in the Left Inverted Terminal Repeat of the Bovine Adenovirus Type 3 Genome Does Not Affect Virus Replication. Intervirology, 2002, 45, 188-192.	2.8	3
56	Characterization of Bovine Adenovirus Type 3 E1 Proteins and Isolation of E1-Expressing Cell Lines. Virology, 2002, 295, 108-118.	2.4	30
57	Sequence analysis of old and new strains of porcine circovirus associated with congenital tremors in pigs and their comparison with strains involved with postweaning multisystemic wasting syndrome. Canadian Journal of Veterinary Research, 2002, 66, 217-24.	1.1	33
58	Tissue Distribution and Genetic Typing of Porcine Circoviruses in Pigs with Naturally Occurring Congenital Tremors. Journal of Veterinary Diagnostic Investigation, 2001, 13, 57-62.	1.1	88
59	Circumvention of Vector-Specific Neutralizing Antibody Response by Alternating Use of Human and Non-Human Adenoviruses: Implications in Gene Therapy. Virology, 2000, 272, 159-167.	2.4	98
60	Sequence Analysis of Porcine Adenovirus Type 3 E1 Region, pIX and pIVa2 Genes, and Two Novel Open Reading Frames. Intervirology, 2000, 43, 6-12.	2.8	7
61	Immunization with DNA, adenovirus or both in biodegradable alginate microspheres: effect of route of inoculation on immune response. Vaccine, 2000, 19, 253-263.	3.8	69
62	Generation of infectious genome of bovine adenovirus type 3 by homologous recombination in bacteria. Journal of Virological Methods, 1999, 77, 125-129.	2.1	18
63	Functional Characterization of Bovine Parainfluenza Virus Type 3 Hemagglutinin-Neuraminidase and Fusion Proteins Expressed by Adenovirus Recombinants. Intervirology, 1998, 41, 253-260.	2.8	4
64	Induction of Systemic and Mucosal Immune Responses in Cotton Rats Immunized with Human Adenovirus Type 5 Recombinants Expressing the Full and Truncated Forms of Bovine Herpesvirus Type 1 Glycoprotein gD. Virology, 1996, 222, 299-309.	2.4	37
65	Foreign Gene Expression by Human Adenovirus Type 5-Based Vectors Studied Using Firefly Luciferase and Bacterial Î²-Galactosidase Genes as Reporters. Virology, 1995, 210, 226-230.	2.4	30
66	Pathogenesis and Immunogenicity of Bovine Adenovirus Type 3 in Cotton Rats (Sigmodon hispidus). Virology, 1995, 213, 131-139.	2.4	35
67	The E1 sequence of bovine adenovirus type 3 and complementation of human adenovirus type 5 E1A function in bovine cells. Virus Research, 1994, 31, 163-186.	2.2	31
68	Monitoring foreign gene expression by a human adenovirus-based vector using the firefly luciferase gene as a reporter. Virus Research, 1993, 28, 67-90.	2.2	148